摘要
目的探讨放射性^(125)I粒子组织间种植治疗转移及复发性骨肿瘤的技术方法和疗效。方法对14例转移及复发性骨肿瘤患者行肿瘤内^(125)I粒子植入治疗,粒子植入数目为3～145颗,粒子活度为18．5～29．6 MBq(0．5～0．8 mCi),肿瘤匹配周边剂量为115～145Gy。术后行质量验证并观察患者临床指标改善情况。结果随访7～29个月(平均12．4个月)。^(125)I粒子治疗90%肿瘤靶体积接受的最小剂量(D_(90))中位值为108．12Gy(27～166Gy),10例脊柱或椎旁肿瘤患者脊髓的中位D_(90)为31．9Gy(6．2～74．0Gy)。粒子植入前伴有疼痛的12例患者,术后疼痛完全缓解率达82%,止痛有效率为92%。10例脊柱或椎旁肿瘤患者中,70%的患者疗后行走能力改善或恢复正常。1年局部控制率为82%,1年生存率为53%,围手术期无3级以上严重并发症发生。结论放射性^(125)I粒子植入安全、高效,是治疗转移及复发性骨肿瘤的一种有前途的新方法。
Objective To assess the value of interstitial ^125I seed implantation for metastatic and recurrent bone neoplasms. Methods From 2002 to 2004 , 14 patients with metastatic or recurrent bone neoplasms were so treated. The number of ^125I seeds implantated ranged from 3-145 with radioactivity varying from 18.5-29.6 MBq. Matched peripheral dose（MPD） of ^125I seed implantation were 115-145Gy. The treatment quality was validated after ^125I seed implantation. Results The median follow-up time was 12.4 months（range 7-29）. The mean D90 to the tumor was 108.12 Gy（ range 27-166 Gy）, with 31.9 Gy（ range 6.2-70.0 Gy） in 10 patients with spinal column or paraspriral lesions. The responsive rate of pain relief was 92%. 70% of the above 10 patients enjoyed either normal or improved ambulation. The 1-year local control rate was 82%, 1-year overall survival rate was 53%. No complications were observed during the periperative period. Conclusion Interstitial ^125I seed implantation is safe and effective in the treatment of metastatic or recurrent bone neoplasms.
出处
《中华放射肿瘤学杂志》
CSCD
北大核心
2006年第5期407-410,共4页
Chinese Journal of Radiation Oncology
关键词
骨肿瘤/放射疗法
肿瘤转移
肿瘤复发
粒子
植入
碘放射性同位素
Bone neoplasms/radiotherapy
Neoplasm metastasis
Neoplasm recurrence
Particles,pellets
Iodine radioisotopes
